Latest Headlines

Latest Headlines

Boehringer's stumble is InterMune's gain in lung drug race

InterMune watched its shares jump more than 15% after Boehringer Ingelheim posted some mixed results for its rival idiopathic pulmonary fibrosis treatment, all while the biotech has nearly tripled in value over the past 30 days.

Report: InterMune eyed for a multibillion-dollar buyout

Fresh off positive results for its late-stage lung drug, InterMune has attracted some M&A interest from a flock of pharmaceutical companies, according to  Reuters, sending the biotech's shares up roughly 12% on Friday.

UPDATED: InterMune rockets up after scoring a big win on PhIII lung drug study

More than three years after the FDA sent InterMune back to the clinic for another Phase III study of its lung drug pirfenidone--Esbriet--for idiopathic pulmonary fibrosis, the biotech says it scored a win on the primary as well as two secondary endpoints for the lung-scarring treatment. And now InterMune says it's ready to go back to the FDA and lay out the data, hoping for an approval that will greatly expand the market for a drug now sold in Europe.

Ex-InterMune CEO's PR rap sheet could leave legal legacy

While W. Scott Harkonen, the former InterMune CEO convicted over an overzealous press release, is notorious in biotech circles, he and his nuanced case of wire fraud could land on a much bigger stage if the Supreme Court decides to listen in.

EMA vows to battle AbbVie in courts for full data transparency

AbbVie and InterMune may have won at least a temporary reprieve in their fight to stop the EMA from releasing trial data on their drugs.

Report: Buyout buzz grows (again) as InterMune perseveres in PhIII

As a pioneer in the fibrosis field, InterMune has often been at the center of considerable buyout buzz. In the spring of 2011, for instance, the company had to pour cold water on fevered speculation that a deal was in the making after its drug Esbriet (pirfenidone) was approved in Europe.

InterMune deal delivers $55M in fresh fuel for fibrosis drug

One of the pioneers in the fibrosis drug field is opting to sell off an aging commercial product to help finance its pipeline work and what it hopes will be a final push for its top prospect in the U.S. market.

Analysts see an upside after market swings bludgeon biotechs

The roller coaster ride investors have been on for the past two weeks underscores an old bit of market wisdom: when the Dow and other indexes catch a cold, biotech gets pneumonia. By Friday analysts

InterMune pours cold water on red-hot takeover rumor

Shares of Brisbane, CA-based InterMune ($ITMN) surged more than five percent yesterday after Bloomberg treated the market to a story that Goldman Sachs had been brought in to scout buyout offers for

Ex-CEO of InterMune sentenced in fraud case

Former InterMune CEO Scott Harkonen has been sentenced to six months of home confinement and ordered to pay a $20,000 fine for his part in disseminating a misleading press release in 2002. He also